Biotech and Pharmaceuticals
CVS shares are up 45% this year — here’s why it may be starting to turn its business around
The CVS pharmacy logo is displayed on a sign above a CVS Health Corp. store in Las Vegas, Nevada, on Feb. 7, 2024. Patrick T. Fallon | AFP | Getty Images After a dismal 2024, CVS Health could be starting to turn itself around. Some investors seem convinced, especially after the retail drugstore chain on […]
Read More
Healthy Returns: What to know about Trump’s NIH funding cuts
Biotech researchers. Janiecbros | E+ | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Trump administration is trying to implement major funding cuts to the National Institutes of Health that would cap […]
Read More
CVS CEO defends pharmacy middlemen, accuses drugmakers of ‘monopolistic’ practices
David Joyner, a longtime CVS executive, speaks during a Senate Health, Education, Labor and Pensions Committee hearing in Washington, D.C., on May 10, 2023. Al Drago | Bloomberg | Getty Images CVS Health CEO David Joyner on Wednesday defended controversial pharmacy middlemen like his company’s Caremark unit, which are widely accused of inflating prescription medication […]
Read More
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer’s treatment Leqembi, saw growth. But the biotech company’s […]
Read More
CVS results top estimates even as high medical costs drag down insurance unit
An exterior view of a CVS pharmacy in Danville, Pennsylvania. Paul Weaver | Lightrocket | Getty Images CVS Health on Wednesday reported fourth-quarter revenue and profit that topped estimates, even as its troubled insurance business continued to see higher medical costs. The company also issued a full-year 2025 adjusted earnings outlook of $5.75 to $6 […]
Read More
We’re adding to our position in a sliding stock and booking profits in a 2025 winner
We’re making a pair of trades Monday as Wall Street rallies to kick off the week. Source
Read More
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a […]
Read More
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term […]
Read More
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw lower realized prices. The figures were consistent with the preliminary results Eli Lilly shared […]
Read More